Exact Sciences Corp EXAS Stock

Summary

Market Closed
$ 49.83
Price Up by 1.47 | 3.04 %
Bid / Size
49.00 × 2
Ask / Size
50.75 × 1
Beta (5-Year)
0.96
Float
165.00 Mil
Short % of Float
4.25
Shares Outstanding
188.64 Mil
Shares Short
7.02 Mil
Shares Short Change
-11.55%
Short Ratio
2.06
Volume / Average
2.6 Mil / 2.9 Mil
Day Range
48.19 – 50.46
Year Range
39.97 – 72.83
as of 2025-07-22
Trailing Returns shows raw returns of the Investment, Category and the Index.
1-Day
1-Week
1-Month
3-Month
YTD
1-Year
3-Year
5-Year
10-Year
15-Year
EXAS 3.04 -5.96 -6.02 12.87 -11.32 3.46 3.16 -12.83 7.02 19.35
Industry 5.23 2.67 2.41 6.70 -10.61 -15.74 -4.86 -0.10 9.30 12.83
Index 0.12 1.16 5.84 19.91 7.91 14.87 18.20 15.12 13.07 14.27

Company Profile EXAS

Business Description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
Sector
Healthcare
Industry
Diagnostics & Research
Most Recent Earnings
Mar 31, 2025
Fiscal Year End
Dec 31, 2025
Employees
7,000

Sustainability

ESG Risk Rating Assessment
Highest Controversy Level (1 = Low, 5 = Severe)
Moderate
Incidents: Business Ethics
ESG Risk Rating
20.85
Medium
Negligible
0–9.99
Low
10–19.99
Medium
20–29.99
High
30–39.99
Severe
40+
Highest Controversy Level (1 = Low, 5 = Severe)
Incidents: Business Ethics
Top Material ESG Issues
Product Governance
Overall
Business Ethics
Overall
Human Capital
Overall

© Morningstar 2025. All Rights Reserved. The data and analyses herein do not constitute investment advice; is provided solely for informational purposes; is not an offer to buy/sell a security; and is not warranted to be correct, complete, or accurate. Morningstar is not responsible for any trading decisions, damages or losses resulting from, or related to, the data and analyses or their use. Financial Professionals: This report may not meet all applicable presentation and/or disclosure standards to which you are subject to by a regulator and may need to be supplemented with another report or additional data and/or disclosures. Review carefully before sharing this report and contact your Compliance team with any questions. The ESG-related information, methodologies, tool, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.